PDS Biotechnology (NASDAQ:PDSB) Trading Down 8.8%

Shares of PDS Biotechnology Co. (NASDAQ:PDSB) fell 8.8% on Friday . The stock traded as low as $2.59 and last traded at $2.65. 881,240 shares were traded during mid-day trading, a decline of 0% from the average session volume of 884,327 shares. The stock had previously closed at $2.90.

Wall Street Analysts Forecast Growth

PDSB has been the subject of several recent research reports. B. Riley reiterated a “buy” rating and set a $11.00 target price (down previously from $14.00) on shares of PDS Biotechnology in a research report on Thursday, March 28th. Cantor Fitzgerald reiterated an “overweight” rating on shares of PDS Biotechnology in a research report on Friday, January 12th. HC Wainwright reiterated a “buy” rating and set a $21.00 target price on shares of PDS Biotechnology in a research report on Wednesday, March 27th. Finally, StockNews.com cut shares of PDS Biotechnology from a “hold” rating to a “sell” rating in a research report on Saturday, March 16th. One research analyst has rated the stock with a sell rating and four have assigned a buy rating to the stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $17.33.

PDS Biotechnology Stock Down 8.8 %

The company has a market cap of $97.02 million, a price-to-earnings ratio of -1.92 and a beta of 1.67. The company has a current ratio of 4.33, a quick ratio of 4.33 and a debt-to-equity ratio of 0.75. The firm’s fifty day moving average price is $4.61 and its 200-day moving average price is $4.87.

PDS Biotechnology (NASDAQ:PDSB) last announced its quarterly earnings results on Wednesday, March 27th. The company reported ($0.34) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.39) by $0.05. Sell-side analysts predict that PDS Biotechnology Co. will post -1.55 earnings per share for the current year.

Hedge Funds Weigh In On PDS Biotechnology

Several institutional investors and hedge funds have recently made changes to their positions in the company. EP Wealth Advisors LLC acquired a new position in PDS Biotechnology in the 3rd quarter worth $52,000. Vontobel Holding Ltd. boosted its stake in PDS Biotechnology by 28.1% in the 3rd quarter. Vontobel Holding Ltd. now owns 41,000 shares of the company’s stock worth $207,000 after purchasing an additional 9,000 shares during the period. Raymond James Financial Services Advisors Inc. acquired a new position in PDS Biotechnology in the 3rd quarter worth $56,000. Inspirion Wealth Advisors LLC boosted its stake in PDS Biotechnology by 1.7% in the 4th quarter. Inspirion Wealth Advisors LLC now owns 336,594 shares of the company’s stock worth $1,733,000 after purchasing an additional 5,720 shares during the period. Finally, Corton Capital Inc. acquired a new position in PDS Biotechnology in the 3rd quarter worth $112,000. Institutional investors and hedge funds own 26.84% of the company’s stock.

About PDS Biotechnology

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, focuses on developing multifunctional cancer immunotherapies. Its lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies.